Review explores whether GLP-1 drugs can redefine transplantation standard of care by addressing post-transplant diabetes, obesity, and cardiovascular risk in organ recipients.
Key findingReview explores whether GLP-1 drugs can redefine transplantation standard of care by addressing post
What the researchers found
Review explores whether GLP-1 drugs can redefine transplantation standard of care by addressing post-transplant diabetes, obesity, and cardiovascular risk in organ recipients.
Why it matters
Relevant to expanding peptide-based therapeutic applications.
The numbers in context
Review covers evidence across solid organ transplant types for GLP-1 drug benefits on metabolism and graft outcomes.
How the study worked
Methodology detailed in publication.
Who was studied
Solid organ transplant recipients with metabolic complications
What this study cannot tell us
Limitations in publication.
How to read the evidence
Based on study design in publication.
When this study was published
Published in 2025.
The bigger picture
Contributes to the growing evidence for peptide therapeutics.
Questions still open
- Long-term implications?
- Comparison to existing evidence?
- Next research steps?
Common questions
What does this mean?
How reliable?
Read the original research
Can GLP-1RAs redefine transplantation standard of care?
Trends in pharmacological sciences, 46(11), 1056-1071
Citation
Almalki, Bassem A. (2025). Can GLP-1RAs redefine transplantation standard of care?. Trends in pharmacological sciences, 46(11), 1056-1071. https://doi.org/10.1016/j.tips.2025.08.013